Partnership leverage Identify and expand joint go-to-market opportunities with large diagnostics and health tech players already collaborating with uMETHOD (e.g., Linus Health, Quest Diagnostics, Tribal Diagnostics) to scale implementation of personalized therapy platforms and AI-assisted care.

AI enabled care Highlight and upsell AI-enabled clinical decision support and patient adherence tools to physicians and health systems through EHR integrations, leveraging existing partnerships to drive adoption of personalized therapy plans.

Cognitive care demand Position uMETHOD as a scalable solution for chronic cognitive diseases where multi-cause etiologies require individualized treatment, targeting brain health specialties, memory clinics, and neurology networks with outcomes driven by progression prevention and potential reversal.

SMB enterprise fit Target mid-market hospitals, clinics, and regional health providers that lack large-scale genomics labs yet need turnkey software-based services for patient and caregiver engagement, progress tracking, and adherence motivation.

Evidence & expansion Build a narrative around clinical and real-world outcomes from current pilots and partnerships to unlock expansion into new territories, capitalizing on revenue visibility and the $10–$25M ARR band to attract mid-tier payers and multi-site accounts.